Sam Brusco, Associate Editor10.11.22
HeartBeam, a company that’s developed the first and only 3D-vector ECG platform to detect heart attacks anytime, has appointed Peter J. Fitzgerald MD, Ph.D., as its chief medical officer.
In addition to world-renowned interventional cardiology expertise, Dr. Fitzgerald is an accomplished inventor, entrepreneur, and investment fund founder. He has been principal and founder of 24 medical device companies in the San Francisco Bay area and transitioned 18 of the start-ups into medium/large-cap life science companies.
“We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” Branislav Vajdic, Ph.D., founder and CEO of HeartBeam, told the press. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.”
He founded TriVentures, an Israel-based incubator and venture fund for early-stage medical technology and digital health, in 2009. He’s also been a consultant to the U.S. Food and Drug Administration (FA) for the past two decades, focused on medical technology and data-driven health analytics.
“HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.”
In addition to world-renowned interventional cardiology expertise, Dr. Fitzgerald is an accomplished inventor, entrepreneur, and investment fund founder. He has been principal and founder of 24 medical device companies in the San Francisco Bay area and transitioned 18 of the start-ups into medium/large-cap life science companies.
“We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” Branislav Vajdic, Ph.D., founder and CEO of HeartBeam, told the press. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.”
He founded TriVentures, an Israel-based incubator and venture fund for early-stage medical technology and digital health, in 2009. He’s also been a consultant to the U.S. Food and Drug Administration (FA) for the past two decades, focused on medical technology and data-driven health analytics.
“HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.”